Department of Gynaecology and Gynaecological Oncology, University Hospital Bonn, Bonn, Germany.
Department of Anaesthesiology, University Hospital Bonn, Bonn, Germany.
Sci Rep. 2021 Nov 23;11(1):22768. doi: 10.1038/s41598-021-02217-y.
Little is known about the specific anaesthesiological and multidisciplinary management of high-intensity focused ultrasound (HIFU) in uterine fibroids. This observational single-center study is the first reporting on an interdisciplinary approach to optimize outcome following ultrasound (US)-guided HIFU in German-speaking countries. A sample of forty patients with symptomatic uterine fibroids was treated by HIFU. Relevant treatment parameters such as total treatment time for intervention, anaesthesia, and sonication time as well as total energy, body temperature, peri-interventional medication and complications were analyzed. Interventional variables did not correlate significantly either with opioid dose or with body temperature. The average fibroid volume reduction rate was 37.8% ± 23.5%, 48.5% ± 22.0% and 70.2% ± 25.5% after 3, 6 and 12 months, respectively. No major anaesthesiological complications occurred apart from an epileptic seizure prior to HIFU treatment in one patient. Peri-procedural hyperthermia (> 37.5 °C) occurred in two patients. Post-procedural two patients experienced a sciatic nerve irritation up to one year; one patient with very large treated fibroid experienced strong short-lasting post-procedural pain. There were two complication-free pregnancies of HIFU-treated patients. Multidisciplinary management is crucial to optimize safety and outcome of US-guided HIFU for uterine fibroids. Peri-procedural pain and temperature management are critical points where an adequate collaboration between anesthesiologist and interventionalist is mandatory.
关于高强度聚焦超声(HIFU)治疗子宫肌瘤的具体麻醉学和多学科管理,目前知之甚少。这项观察性单中心研究首次报告了德国多学科方法优化超声(US)引导 HIFU 治疗后的结果。40 例有症状的子宫肌瘤患者接受了 HIFU 治疗。分析了相关的治疗参数,如干预、麻醉和超声时间的总治疗时间以及总能量、体温、围手术期药物和并发症。介入变量与阿片类药物剂量或体温均无显著相关性。平均肌瘤体积减少率分别为治疗后 3、6 和 12 个月时的 37.8%±23.5%、48.5%±22.0%和 70.2%±25.5%。除 1 例患者在 HIFU 治疗前出现癫痫发作外,无重大麻醉并发症。2 例患者在围手术期出现体温升高(>37.5°C)。2 例患者在术后 1 年内出现坐骨神经刺激;1 例接受非常大的治疗肌瘤的患者出现强烈的短期术后疼痛。有 2 例 HIFU 治疗的患者进行了无并发症的妊娠。多学科管理对于优化 US 引导 HIFU 治疗子宫肌瘤的安全性和疗效至关重要。围手术期疼痛和体温管理是关键,麻醉师和介入医生之间需要充分合作。